Figure 5.
Figure 5. PD-L1 signature was validated in primary DLBCL samples. (A) Scatter plots comparing CD274, STAT3, and IL-10 mRNA expression levels in GCB vs ABC subtypes of DLBCL. (B) Scatter plots comparing PD-L1 and pSTAT3 protein expression in GCB vs ABC DLBCL subtypes. (C) Scatter plots comparing pSTAT3 protein expression, as well as STAT3 and IL-10 mRNA expression, in PD-L1+ vs PD-L1− DLBCL cases. (D) Scatter plots comparing PD-L1 protein expression and IL-10 mRNA expression levels in pSTAT3lo/pSTAT3− vs pSTAT3hi/pSTAT3+ DLBCL cases. (E) Scatter plots comparing CXCL10 mRNA levels in GCB vs ABC, PD-L1− vs PD-L1+, and pSTAT3− vs pSTAT3+ DLBCL.

PD-L1 signature was validated in primary DLBCL samples. (A) Scatter plots comparing CD274, STAT3, and IL-10 mRNA expression levels in GCB vs ABC subtypes of DLBCL. (B) Scatter plots comparing PD-L1 and pSTAT3 protein expression in GCB vs ABC DLBCL subtypes. (C) Scatter plots comparing pSTAT3 protein expression, as well as STAT3 and IL-10 mRNA expression, in PD-L1+ vs PD-L1 DLBCL cases. (D) Scatter plots comparing PD-L1 protein expression and IL-10 mRNA expression levels in pSTAT3lo/pSTAT3 vs pSTAT3hi/pSTAT3+ DLBCL cases. (E) Scatter plots comparing CXCL10 mRNA levels in GCB vs ABC, PD-L1 vs PD-L1+, and pSTAT3 vs pSTAT3+ DLBCL.

Close Modal

or Create an Account

Close Modal
Close Modal